Site menu:

RSS AlertNet

Site search

Categories

October 2006
M T W T F S S
« Sep   Nov »
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Archive

Capital confusions

taking 2 20 mg cialis how does solumedro work with prevacid can you take lyrica with soma successs storys of people on prozac order cialis on-line celebrex interaction with other drugs lipitor drug class prometrium manufactured proscar buy online seroquel swollen hands does synthroid cause hair loss oxytrol transdermal system xeloda reload atarax tablet cialis blood levels zocor and nausea with vomiting renewal hgh workout pravachol fatty liver does walmart sell hoodia nervous system agitation effexor colchicine minnesota propecia success lopid profile cla architecture inc paxil alcholism zyvox iv effexor paxil baby make clomid light test melatonin dosage dogs tramadol for sle side effects of celexa in elderly effexor syndrome aura soma oracle viagra in pharmacy in ottawa fosamax and unwanted side effects patient assistance program aciphex weight gain and effexor proper dose and melatonin and dogs generic toprol xl reported side effects chitosan gras requip starter pack dosage jaw necrosis and fosamax singulair effectivenes and impact on strength boston affordable hgh propecia 5mg breast enhancement scams risperdal interactions tramadol no prior overnight thrush sinus prednisone when will viagra be genaric

There’s capital and there’s capital.

  1. This comment is good.
  2. If big pharma thought capitalising R&D was a good idea they would be doing it already.
  3. What makes sense for big pharma does not necessarily make sense for aggregate calculations.
  4. That’s not comforting if you want to be precise about capital.

Posted: October 7th, 2006 under Unsorted.
Comments: none

Write a comment





FireStats iconPowered by FireStats